Townsquare Capital LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Townsquare Capital LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 219.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,804 shares of the biotechnology company's stock after purchasing an additional 2,615 shares during the quarter. Townsquare Capital LLC's holdings in United Therapeutics were worth $1,342,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealthfront Advisers LLC increased its stake in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the last quarter. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth approximately $151,764,000. FMR LLC boosted its stake in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after buying an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans grew its position in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock valued at $72,085,000 after acquiring an additional 189,967 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock worth $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $940,373.07. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,500 shares of company stock worth $30,971,540 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 0.2 %

United Therapeutics stock traded down $0.46 on Friday, hitting $284.73. 302,945 shares of the stock traded hands, compared to its average volume of 452,318. The business's fifty day simple moving average is $316.61 and its 200 day simple moving average is $348.62. The firm has a market cap of $12.79 billion, a P/E ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 1 year low of $233.28 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the firm earned $4.36 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.